The Sex - During this treatment for breast cancer can also kill
healthy cells. Now the experts managed to create 'smart bombs' that could
deliver toxic to tumor cells but do not keep or kill healthy cells.
In tests involving almost 1,000 women with advanced stage, this experimental treatment can extend the life of women up to several months without the cancer getting worse.
After two years of about 65 percent of women who received this treatment were still alive up to 10 months compared with the group receiving standard cancer drug 2 only 47 percent who survive up to 6 months.
"The difference in the absolute look of a larger number on how long people can survive. This is a great step of progress," said Dr. Kimberly Blackwell of Duke University, as quoted by FoxNews on Monday (06/04/2012) .
Herceptin treatment is based on who is the first targeted gene therapy for breast cancer. Researchers are combining Herceptin with chemotherapy is toxic and coupled with a chemical to keep them in order to achieve the target of the cancer cells where toxins are released later to kill the cell.
Ganda weapon used by T-DM1 is called smart bombs, although not all smart, but these substances bind to cancer cells only after meeting her. Researchers tested the T-DM1 at 991 women with breast cancer spreading and getting worse despite receiving regular chemotherapy and Herceptin.
Dr. Blackwell said that proved there is an increased overall survival, as well as T-DM1 has fewer side effects in addition to other drugs, patients do not need drugs nausea and unnecessary transfusions.
"These data are quite interesting, so it's kind of smart bomb type of therapy where toxins delivered to the tumor so that not much damage to other organs," said Dr. Michael Link, president of the American Society of Clinical Oncology.
However, they are smart bombs still in the experimental or research that is not yet available. Yet this drug is expected within a year can have on the market.
In tests involving almost 1,000 women with advanced stage, this experimental treatment can extend the life of women up to several months without the cancer getting worse.
After two years of about 65 percent of women who received this treatment were still alive up to 10 months compared with the group receiving standard cancer drug 2 only 47 percent who survive up to 6 months.
"The difference in the absolute look of a larger number on how long people can survive. This is a great step of progress," said Dr. Kimberly Blackwell of Duke University, as quoted by FoxNews on Monday (06/04/2012) .
Herceptin treatment is based on who is the first targeted gene therapy for breast cancer. Researchers are combining Herceptin with chemotherapy is toxic and coupled with a chemical to keep them in order to achieve the target of the cancer cells where toxins are released later to kill the cell.
Ganda weapon used by T-DM1 is called smart bombs, although not all smart, but these substances bind to cancer cells only after meeting her. Researchers tested the T-DM1 at 991 women with breast cancer spreading and getting worse despite receiving regular chemotherapy and Herceptin.
Dr. Blackwell said that proved there is an increased overall survival, as well as T-DM1 has fewer side effects in addition to other drugs, patients do not need drugs nausea and unnecessary transfusions.
"These data are quite interesting, so it's kind of smart bomb type of therapy where toxins delivered to the tumor so that not much damage to other organs," said Dr. Michael Link, president of the American Society of Clinical Oncology.
However, they are smart bombs still in the experimental or research that is not yet available. Yet this drug is expected within a year can have on the market.
No comments:
Post a Comment